Business
Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention
NEW HAVEN, Conn., June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention. In addition, Ms. Good will be participating in partnership meetings throughout the conference alongside Farrell Simon, SVP, Head of Commercial and Strategy. The 2022 BIO International Convention will be held in person from June 13-16, 2022 in San Diego, CA.\n\n \n \n \n \n \n \n\n \nTrevi's President and CEO, Jennifer Good, will present at the BIO International Convention on June 13 at 4 pm PTBIO International Convention and Presentation DetailsDate: June 13-16, 2022Presentation Time: June 13th at 4:00 PM PTPresentation Room: Theater 1Location: San Diego Convention Center, San Diego, CA\nThe BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. The event brings together a wide spectrum of life science and application innovators, including drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.\nTo register for the event, please click here.\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in adults with idiopathic pulmonary fibrosis (IPF). These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.\nFounded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.\nAbout HaduvioHaduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more tha...